MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
QIAGEN N.V. Market Cap 2011-2026 | QGEN
As of May 15, 2026 QIAGEN N.V. has a market cap of $ 10.6 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 8.52 B | 10 B | 9.8 B | 11.3 B | 11.4 B | 8.14 B | 8.71 B | 7.69 B | 6.44 B | 5.3 B | 5.33 B | 5.2 B | 4.98 B | 3.83 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 B | 3.83 B | 7.62 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.29 | -20.63 % | $ 1.72 M |  USA |
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Fulgent Genetics
FLGT
|
467 M | $ 15.93 | -1.61 % | $ 482 M | USA |
 |
Agilent Technologies
A
|
42 B | $ 112.11 | -1.0 % | $ 34.1 B | USA |
 |
Castle Biosciences
CSTL
|
472 M | $ 19.08 | 1.06 % | $ 553 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 140.65 | -1.81 % | $ 22.4 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.8 | - | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 19.81 | -3.32 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 93.98 | -2.78 % | $ 6.34 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 419.51 | 0.08 % | $ 12.1 B | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 046.9 | 0.48 % | $ 21.6 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Myriad Genetics
MYGN
|
409 M | $ 3.61 | -0.28 % | $ 334 M | USA |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.28 | -1.02 % | $ 1.06 B | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 155.13 | -2.51 % | $ 7.69 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 18.58 | -1.85 % | $ 416 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 187.34 | -4.86 % | $ 18.4 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.3 B | $ 25.34 | -0.65 % | $ 24 B |  Niderland |
 |
Guardant Health
GH
|
13.4 B | $ 93.18 | -5.56 % | $ 11.7 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 5.73 | -1.63 % | $ 239 M | USA |
 |
Personalis
PSNL
|
431 M | $ 6.5 | -3.2 % | $ 580 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 117.79 | 0.6 % | $ 9.72 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 52.99 | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.36 | -2.07 % | $ 5.42 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 252.4 | -0.64 % | $ 21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 441.45 | -1.49 % | $ 166 B | USA |
 |
Trinity Biotech plc
TRIB
|
194 M | $ 0.57 | -1.7 % | $ 205 M | Irlanda |
 |
Celcuity
CELC
|
5.37 B | $ 134.95 | 0.17 % | $ 6.31 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 48.89 | -7.67 % | $ 2.92 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 8.28 | -1.78 % | $ 1.8 B | USA |
 |
Waters Corporation
WAT
|
19.7 B | $ 332.25 | -0.29 % | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 186.87 | -0.57 % | $ 20.7 B | USA |